SG
CYTK icon

Stonnington Group’s Cytokinetics CYTK Stock Holding History

Stonnington Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$298K Buy
+8,300
New +$339K 0.08% 187

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Stonnington Group's CYTK Position: Q1 2023 in Review

Stonnington Group opened a new position in Cytokinetics (CYTK) in Q1 2023: 8,300 shares worth $298K. The stake represents 0.08% of the portfolio and ranks #187 among its holdings.

262 funds tracked by Wall St. Rank hold CYTK as of Q1 2023.

  • Stonnington Group held 8,300 shares of Cytokinetics worth $298K as of Q1 2023.
  • Cytokinetics was a new Stonnington Group position in Q1 2023.
  • Cytokinetics made up 0.08% of Stonnington Group's portfolio in Q1 2023, its #187 holding.
  • 262 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2023.

Based on Stonnington Group's 13F filing for Q1 2023, filed 14 Apr 2023.